Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Current Leases (2020 - 2025)

SAB Biotherapeutics' Current Leases history spans 6 years, with the latest figure at $153967.0 for Q4 2025.

  • For Q4 2025, Current Leases fell 60.87% year-over-year to $153967.0; the TTM value through Dec 2025 reached $153967.0, down 60.87%, while the annual FY2025 figure was $153967.0, 60.87% down from the prior year.
  • Current Leases reached $153967.0 in Q4 2025 per SABSW's latest filing, down from $837286.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.2 million in Q3 2022 to a low of $132788.0 in Q4 2022.
  • Average Current Leases over 5 years is $630843.0, with a median of $545964.0 recorded in 2023.
  • Peak YoY movement for Current Leases: tumbled 88.38% in 2022, then skyrocketed 494.15% in 2025.
  • A 5-year view of Current Leases shows it stood at $1.1 million in 2021, then crashed by 88.38% to $132788.0 in 2022, then soared by 404.52% to $669946.0 in 2023, then tumbled by 41.27% to $393430.0 in 2024, then crashed by 60.87% to $153967.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Current Leases are $153967.0 (Q4 2025), $837286.0 (Q3 2025), and $815064.0 (Q2 2025).